Chief Medical Officer (CMO)


This is a unique opportunity to be a major contributor to the success of a dynamic and growth stage biotechnology company, Cinclus Pharma AB.

The Chief Medical Officer (CMO) will have the overall medical and clinical development responsibility including the ongoing phase 2 and planned phase 3 studies. He/she will ensure an appropriate and continuous medical risk/benefit assessment and will execute a risk minimisation at all stages to secure a sound and ethical development of a safe drug product.

He/she will contribute to establish collaborative relationships with the investigators to ensure an efficient and timely execution of the program. As a speaking partner he/she will provide information about GERD and linaprazan glurate through visits to the clinics and virtual meetings.

The CMO will is responsible for the clinical development program with focus on the Phase 3 studies that will be initiated during 2022. The CMO will provide medical and clinical development input into clinical programmes from the clinical/scientific and strategic prospective.  He/she is also responsible for clinical key documents such as CDP’s, IB’s, protocols, reports and clinical parts of key TPPs and IMPDs. The CMO will provide his/ her expertise in the evaluation of data generated in the clinical trials and will also contribute to the company PR and Communication strategy.  The CMO will also interact with KOLs and PIs globally and be in charge for advisory boards.

The CMO is part of the management team.

Your profile

 We are primarily looking for an experienced medical doctor, having a strong background in clinical operations. We are also welcoming applicants with a medical advisor background, a medical doctor degree and preferably experience from gastroenterology, internal medicine or surgery, and solid experience in clinical trials from a HQ perspective.


  • Medical Doctor / Physician with a PhD
  • Experience from the pharmaceutical industry, extensively involved in clinical trials from a HQ perspective
  • Excellent skills in English, orally and written


Preferred (but not must)

  • Medical expertise in gastroenterology, internal medicin or surgery
  • Proven track record of working in start-ups or in small biotech companies or from head quarters, not only big pharma
  • Experience in clinical phases of drug development from early phases to commercialisation


Personal Attributes

  • Self going, creative and solution oriented person
  • Open to work in an entrepreneurial and growing organization, where ownership, collaboration and own drive is of greatest importance
  • Hands-on approach as well as strategic capability
  • Ability and willingness to international travelling


Apply today!

To apply, please send your CV and a cover letter asap to Daniel Kremer at; If you have questions regarding this open position, please contact Daniel at +46 (0)733 87 27 24.


By submitting your application, you also consent to us storing your personal data, including CV & cover letter and that we have the right to share this information with third parties (our client). You can revoke the consent whenever you want.

Cinclus Pharma AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. The company was founded in 2014 by Kjell Andersson, Peter Unge, Lennart Hansson, Mikael Dahlström, Urban Paulsson and Marek Poszepczynski. The members of Cinclus Pharma’s management team were key members of the project teams that developed AstraZeneca’s blockbuster drugs Losec and Nexium.

Cinclus Pharma’s drug candidate linaprazan glurate represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. The beneficial safety and pharmacokinetic properties of linaprazan glurate have been documented in phase I studies. The Phase 2 study is ongoing in Europe and the US.

Linaprazan glurate is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca.  Linaprazan has been evaluated in 23 phase I, and two phase II studies in a total of approximately 2,500 subjects. Linaprazan glurate is being developed for treatment of severe Gastroesophageal reflux disease (GERD)and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs.

Based on epidemiological data, the estimated size of this target population is 18.5 million and carries a Blockbuster potential (estimated sales exceeding USD 1 bn).